Log In
BCIQ
Print this Print this
 

AZD2098

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCC chemokine receptor 4 (CCR4; CD194) antagonist
Molecular Target CC chemokine receptor 4 (CCR4) (CD194)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationRenal cancer
Indication DetailsTreat kidney cancer
Regulatory Designation
PartnerCancer Research Technology Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/20/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today